Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.

ABSTRACT:

Purpose

We sought to determine the most cost-effective treatment for patients with newly diagnosed neovascular macular degeneration: monthly or as-needed bevacizumab injections, or monthly or as-needed ranibizumab injections.

Design

Cost-effectiveness analysis.

Participants

Hypothetical cohort of 80-year-old patients with newly diagnosed neovascular macular degeneration.

Methods

Using a mathematical model with a 20-year time horizon, we compared the incremental cost-effectiveness of treating a hypothetical cohort of 80-year-old patients with newly diagnosed neovascular macular degeneration using monthly bevacizumab, as-needed bevacizumab, monthly ranibizumab, or as-needed ranibizumab. Data came from the Comparison of Age-related macular degeneration Treatment T

SUBMITTER: Stein JD 

PROVIDER: S-EPMC4109727 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature